Anti-factor xii/xiia antibodies and uses thereof

An antibody, factor technology, used in the field of therapy and diagnosis, to solve problems such as increased bleeding risk

Pending Publication Date: 2021-03-02
REGENERON PHARM INC
View PDF32 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anticoagulants currently used in the field, such as heparin, are effec

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-factor xii/xiia antibodies and uses thereof
  • Anti-factor xii/xiia antibodies and uses thereof
  • Anti-factor xii/xiia antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0088] Production of Human Antibodies

[0089] Methods for generating human antibodies in transgenic mice are known in the art. Any such known method can be used in the context of the present invention to make human antibodies that specifically bind to FXII and / or FXIIa.

example

[0160] The following examples are set forth to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (eg amounts, temperature, etc.), but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, room temperature is about 25° C., and pressure is at or near atmospheric.

example 1

[0161] Example 1: Generation of Human Antibodies Against Factor XII / Activated Factor XII (FXII / FXIIa) Proteins

[0162] In DNA that encodes the variable regions of human immunoglobulin heavy chains and kappa light chains Human antibodies to FXII / FXIIa proteins are produced in mice. Mice were immunized with plasma purified human FXII and FXIIa proteins (Enzyme Research Laboratories).

[0163] Anti-FXII antibodies were isolated directly from antigen-positive mouse B cells without fusion to myeloma cells as described in US Patent 7,582,298, which is expressly incorporated herein by reference in its entirety. Using this method, several fully human anti-FXII antibodies (ie, antibodies with human variable domains and human constant domains) were obtained; exemplary antibodies generated in this way are designated mAb26036, mAb26048, mAb26049 and mAb26076.

[0164] The biological characteristics of exemplary antibodies produced according to the methods of this example are described...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.

Description

[0001] related application [0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 687,144, filed June 19, 2018, which is hereby incorporated by reference in its entirety. [0003] sequence listing [0004] This application contains a Sequence Listing, which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on June 18, 2019, is named 10463WO01_SL.txt and is 26,288 bytes in size. technical field [0005] The present invention relates to antibodies and antibody antigen-binding fragments that specifically bind to coagulation factor XII, and therapeutic and diagnostic methods using those antibodies. Background technique [0006] Coagulation factors, as well as platelets, are blood components involved in the process of hemostasis during vascular injury. It is recognized that these components can be drivers of thrombosis when regulation (ie, production...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P7/02C07K16/36
CPCC07K2317/76C07K2317/21C07K2317/92C07K16/36A61P7/02A61K2039/505C07K2317/565H03F3/45475H03F2203/45444
Inventor D·夏洛索恩L·C·莫顿L·米特瑙尔K·莱
Owner REGENERON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap